In pricing its new amyotrophic lateral sclerosis drug Relyvrio, Amylyx Pharmaceuticals chose a sum that’s just below the current cost of the last ALS drug to win FDA approval. But a drug price watchdog group argues that prices should be set based on therapeutic value, not according to the price of existing medications.
The health technology assessment group and the New York-based company announced their partnership Monday. ICER also plans to use RWE in assessing drugs that have accelerated FDA approval.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The nonprofit called out seven drugmakers in its report on "unsupported price increases" Tuesday. Drugmakers criticized the organization's methodology in response.
The report found that Aimmune's AR101 and DBV's Viaskin Peanut lacked sufficient evidence to demonstrate that their benefits outweighed short-term risks. Aimmune and an allergy advocacy group criticized the report.
The PBM will incorporate cost-per-QALY analyses from ICER, but the program also drew some criticism.
A forum convened by patient advocates will serve as the launching event for the ICER Watch patient portal, which will track the movements of the Institute for Clinical and Economic Review, which last month released a report on the effectiveness of treatment options for multiple myeloma.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Future topics will include lower back pain, ADHD and type 2 diabetes.